title: Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice.
abstract: We have previously shown that low density lipoprotein receptor-deficient (LDL-RD) mice immunized with beta2-glycoprotein I (beta2GPI; a target of autoimmune anticardiolipin antibodies) developed enhanced early atherosclerosis, when fed a normal chow diet. The current study was undertaken to evaluate the effect of immunization with beta2GPI and the addition of a high fat diet on the progression of atherosclerosis in the apolipoprotein E (ApoE)-deficient mouse. Six-week-old female ApoE-deficient mice (n = 10) were immunized subcutaneously with either human beta2GPI or with ovalbumin, both emulsified in complete Freund's adjuvant and fed a high fat diet for 6 weeks. The beta2GPI-immunized mice were found to develop accelerated atherosclerosis when compared with their ovalbumin-immunized littermates (aortic lesion area of 137,500 +/- 13,801 vs. 72,444 +/- 14,465 microm2, respectively; p = 0.0067). The beta2GPI-immunized mice developed high titers of anti-beta2GPI antibodies, 10 days after the procedure, which were sustained until the sacrifice. LDL extracted from both study groups displayed similar susceptibility to ex vivo oxidation. These results confirm our previous study in which we found increased atherosclerosis in beta2GPI-immunized LDL-RD mice fed a chow diet. In the current study we show that the proatherogenic effect of beta2GPI immunization is maintained despite high cholesterol levels and is not associated with increased susceptibility of LDL to ex vivo oxidation.
authors.affiliation: Institute of Pathology, Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Afek
authors.forename: J
authors.initials: J
authors.lastname: George
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
authors.forename: B
authors.initials: B
authors.lastname: Gilburd
authors.forename: Y
authors.initials: Y
authors.lastname: Levy
authors.forename: A
authors.initials: A
authors.lastname: Shaish
authors.forename: P
authors.initials: P
authors.lastname: Keren
authors.forename: Z
authors.initials: Z
authors.lastname: Janackovic
authors.forename: I
authors.initials: I
authors.lastname: Goldberg
authors.forename: J
authors.initials: J
authors.lastname: Kopolovic
authors.forename: D
authors.initials: D
authors.lastname: Harats
mesh_terms: D000818:Animals; D000906:Antibodies / Q000097:blood; D000918:Antibody Specificity; D001057:Apolipoproteins E / Q000172:deficiency*; D001161:Arteriosclerosis / Q000209:etiology* / Q000378:metabolism; D004041:Dietary Fats / Q000009:adverse effects; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007114:Immunization; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D018110:Receptors, Lipoprotein / Q000172:deficiency; D012307:Risk Factors; D053482:beta 2-Glycoprotein I
chemical_list: D000906:Antibodies; D001057:Apolipoproteins E; D004041:Dietary Fats; D006023:Glycoproteins; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D018110:Receptors, Lipoprotein; D053482:beta 2-Glycoprotein I; D010047:Ovalbumin